Bexxar^®: Novel Radioimmunotherapy for the Treatment of Low-grade and Transformed Low-grade Non-Hodgkin's Lymphoma

Bexxar®: Novel Radioimmunotherapy for the Treatment of Low-grade and Transformed Low-grade Non-Hodgkin's Lymphoma Julie M. Vose Oncologist 2004; 9: 160-172 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in lymphomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe advances in clinical radioimmunotherapy. Discuss ongoing translational research in radioimmunotherapy. Identify future directions for radioimmunotherapy in cancer medicine. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Mar. 26, 2004 Most Recent Review: Mar. 26, 2004* Most Recent Update: Mar. 26, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.